Orion - Company Announcement

Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Stalevo® in the United States

ORION CORPORATION STOCK EXCHANGE RELEASE 26 March 2012 at 09.00  EEST

Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version
of Orion's proprietary drug Stalevo® (carbidopa/levodopa/entacapone) in the
United States

Company states generic competition is not imminent based on this application.

Orion Corporation has been informed that an Abbreviated New Drug Application
(ANDA) has been filed by Mylan Pharmaceuticals Inc. (Mylan) with the U.S. Food
and Drug Administration (FDA) seeking authorisation to produce and market
generic tablets (strengths 12,5/50/200 mg; 18,75/75/200 mg; 25/100/200 mg;
31,25/125/200 mg; 37,5/150/200 mg and 50/200/200 mg) in the United States, with
carbidopa, levodopa and entacapone as active ingredients in the same proportion
as in Orion's Stalevo®.  The product is an enhanced levodopa treatment
originated by Orion Corporation and marketed in the United States by its
exclusive licensee, Novartis, for the treatment of Parkinson's disease.

At this point, the ANDA review process of Mylan is just beginning in the United
States and generic competition is not imminent based on this application.

Mylan has filed the so-called Paragraph IV certifications challenging Orion U.S.
patents No. 5,446,194 No. 6,500,867 and No. 6,797,732 covering Orion's product
Stalevo® and listed in the Orange Book, the FDA's official listing of approved
drug products.

Paragraph IV certifications are not uncommon in the U.S. Orion is currently
evaluating together with Novartis its legal options to protect its rights. Under
the U.S. system, if a patent owner brings a lawsuit against an ANDA applicant
within a certain time limit, there will be a 30-month stay of final FDA
approval. During that time, the FDA can give only a tentative approval to the
ANDA applicant unless the applicant obtains a favorable decision on all
challenged patents in the lawsuit.


Orion Corporation

 Timo Lappalainen  Olli Huotari
 President and CEO SVP, Corporate Functions

Contact person:
Olli Huotari, Senior VP, Corporate Functions, phone +358 10 426 3054, gsm
+358 50 966 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.

Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



[HUG#1597065]